Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio Pharma BBIO shares have gained 24% in the past three months, far ahead of the S&P 500’s 0.7% rise over the same period. The move leaves investors weighing whether improving commercial and pipeline momentum can support further gains.

Attruby’s growth and multiple regulatory catalysts strengthen the fundamental case. Still, a rich valuation and meaningful execution risk leave less room for disappointment after the recent advance.

BBIO’s Three-Month Rally Sets a Higher Bar

The stock’s three-month gain extends a much larger 71.4% advance over the past year. That compares with gains of 6.6% for its Zacks sub-industry and 12.4% for the Zacks Medical sector over three months.

Over the past year, the sub-industry and sector rose 32.5% and 13.1%, respectively. BBIO’s outperformance raises the bar for future results, making continued operating progress more important as investors assess the next leg of the stock’s move.

Attruby Growth Gives BBIO Fundamental Support

Attruby generated $403 million in U.S. sales during the first half of 2026 after producing $362.4 million in 2025. BridgeBio also said Attruby continued gaining share among treatment-naive patients in the second quarter, while diagnosed ATTR-CM patients in the United States exceeded 50,000 in 2025.

The competitive backdrop remains important. Pfizer Inc. PFE remains an established competitor through the Vyndaqel family. Alnylam Pharmaceuticals, Inc. ALNY also competes with Amvuttra in ATTR-CM. Continued first-line adoption and broader diagnosis will therefore be key to sustaining Attruby’s growth.

BridgeBio Pharma, Inc. Price and EPS Surprise

 

 

 

 

 

 

 

 

BridgeBio Pharma, Inc. price-eps-surprise | BridgeBio Pharma, Inc. Quote

BBIO’s Pipeline Adds Near-Term Upside Catalysts

BBP-418 is the closest major regulatory event, with an FDA decision expected by Nov. 27, 2026, for limb-girdle muscular dystrophy type 2I/R9. If approved, it could become the first therapy for that patient population, and BridgeBio has said it is prepared to launch upon approval.

Encaleret has an FDA decision date of May 8, 2027, for autosomal dominant hypocalcemia type 1. Infigratinib adds another potential launch, with BridgeBio targeting early to mid-2027 in achondroplasia. Successful approvals would broaden the commercial base beyond Attruby.

Valuation Could Limit Further BBIO Upside

BBIO trades at 12.0X forward 12-month EV/Sales, well above 2.9X for its Zacks sub-industry and 2.6X for the Zacks Medical sector. The S&P 500 trades at 4.8X on the same measure.

That premium leaves less valuation support if commercial execution slows or regulatory outcomes disappoint. Continued Attruby growth and successful pipeline conversion may be needed for the stock to sustain a premium multiple after its recent rally.

BBIO’s Mixed Signals Keep Expectations in Check

The bottom line is that BBIO has credible growth drivers, but the stock already discounts meaningful progress. Attruby is scaling quickly and several late-stage assets could diversify revenues, while competition, regulatory risk and valuation remain important offsets.

BBIO currently carries a Zacks Rank #3 (Hold), with a Growth Score of B, Value Score of F, Momentum Score of D and VGM Score of D. The favorable Growth Score points to stronger growth characteristics, but the weaker value, momentum and combined scores temper the near-term setup. That mix supports a measured view rather than assuming the three-month rally will continue at the same pace. 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research